1
|
David C, Frémond ML. [When to consider type I interferonopathy in adulthood?]. Rev Med Interne 2022; 43:347-355. [PMID: 35177256 DOI: 10.1016/j.revmed.2021.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 11/15/2021] [Accepted: 11/28/2021] [Indexed: 10/19/2022]
Abstract
Type I interferonopathies (IP1) are a heterogeneous group of Mendelian diseases characterized by overactivation of the type I interferon (IFN) pathway. They are caused by monogenic (rarely digenic) mutations of proteins involved in this key pathway of innate immunity. IP1 transmission can be dominant, recessive or X-linked and penetrance differs from one IP1 to another. The clinical spectrum is broad and mainly includes central nervous system involvement with calcifications of the basal ganglia, skin disorders such as cutaneous vasculitis that can be mutilating. Joint disorders including non-destructive deforming arthropathy, pulmonary involvement such as intra-alveolar haemorrhage or interstitial lung disease, and haematological symptoms with cytopenia and/or immune deficiency are also seen. The clinical manifestations vary from one IP1 to another and their spectrum is constantly expanding along with the description of new IP1s and patients. The inflammatory syndrome is generally mild and autoimmune stigmata are frequently found. Almost all patients display overexpression of the type I IFN pathway detected, for instance, by the evaluation of IFN-stimulated genes expression, referred as "interferon signature". The related morbidity and mortality are high. However, the beneficial effect on certain symptoms of targeted therapies inhibiting type I IFN, such as JAK inhibitors, has led to a promising improvement in the management of these patients.
Collapse
Affiliation(s)
- C David
- Université de Paris, Institut Imagine, laboratoire de neurogénétique et neuroinflammation, 24, boulevard du Montparnasse, 75015 Paris, France
| | - M-L Frémond
- Université de Paris, Institut Imagine, laboratoire de neurogénétique et neuroinflammation, 24, boulevard du Montparnasse, 75015 Paris, France; Unité d'immuno-hématologie et rhumatologie pédiatriques, centre de référence des maladies rhumatologiques et auto-immunes systémiques rares en pédiatrie (RAISE), hôpital Necker-Enfants-Malades, Centre - Université de Paris, AP-HP, 75015 Paris, France.
| |
Collapse
|
2
|
Bonny V, Maillard A, Mousseaux C, Plaçais L, Richier Q. [COVID-19: Pathogenesis of a multi-faceted disease]. Rev Med Interne 2020; 41:375-389. [PMID: 32507520 PMCID: PMC7250743 DOI: 10.1016/j.revmed.2020.05.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 05/13/2020] [Accepted: 05/16/2020] [Indexed: 02/07/2023]
Abstract
SARS-CoV-2 infection, named COVID-19, can lead to a dysregulated immune response and abnormal coagulation responsible for a viral sepsis. In this review, we specify physiopathological mechanisms of each phase of COVID-19 - viral, immune and pro-thrombotic - notably because they involve different treatment. Finally, we specify the physiopathological mechanisms of organ injury.
Collapse
Affiliation(s)
- V Bonny
- Interne en DES de pneumologie, Sorbonne-université, France
| | - A Maillard
- Interne en DES de maladies infectieuses, MSc, Université de Paris, France
| | - C Mousseaux
- DES de néphrologie, MSc, Sorbonne-université, France
| | - L Plaçais
- Interne en DES de médecine interne, MSc, Sorbonne-université, France
| | - Q Richier
- Interne en DES de médecine interne Paris, MSc, Université de Paris, France.
| |
Collapse
|
3
|
Ait-Oufella H, Libby P, Tedgui A. Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases. Arch Cardiovasc Dis 2020; 113:5-8. [PMID: 31917124 DOI: 10.1016/j.acvd.2019.11.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 10/25/2022]
Affiliation(s)
- Hafid Ait-Oufella
- Université de Paris, Inserm U970, Paris Cardiovascular Research Center, Paris, France; Sorbonne Université, Service de Réanimation Médicale, Hôpital Saint-Antoine, AP-HP, Paris, France.
| | - Peter Libby
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
| | - Alain Tedgui
- Université de Paris, Inserm U970, Paris Cardiovascular Research Center, Paris, France
| |
Collapse
|
4
|
Houzé S. [Malaria: immuno-permissive management in the prevention of transfusional malaria]. Transfus Clin Biol 2019; 26:192-194. [PMID: 31331829 DOI: 10.1016/j.tracli.2019.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Accepted: 07/08/2019] [Indexed: 10/26/2022]
Abstract
Malaria is a potentially life-threatening tropical infectious disease caused by a parasite that infects erythrocytes. Its transmission is vectorial, but the transfusion of infected red blood cells can cause a delicate diagnosis of transmitted malaria. Prevention is based on the selection of donors at risk by the search for antibodies reflecting past infection, in the absence of a sufficiently sensitive parasite detection technique to prevent all risks. Recent cases of transfusion malaria have reiterated that this preventive measure does not allow screening of all asymptomatic carriers.
Collapse
Affiliation(s)
- S Houzé
- CNR du Paludisme, hôpital Bichat, AP-HP, 46, rue Henri Huchard, 75018 Paris, France.
| |
Collapse
|
5
|
Vano YA, Simonaggio A, Thibault C, Oudard S. Immunothérapie des cancers du rein. Bull Cancer 2019; 105 Suppl 1:S24-S34. [PMID: 30595195 DOI: 10.1016/s0007-4551(18)30387-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
IMMUNOTHERAPY FOR RENAL CELL CARCINOMA Clear cell kidney cancer is a tumour type whose development and progression is driven by the HIF/VEGF angiogenesis pathway. Anti-angiogenic (AA) agents, particularly anti-VEGFR tyrosine kinase (TKI) inhibitors, have profoundly modified the prognosis of patients in the metastatic setting (mRCC) since their registration in 2006. At the same time, mTOR inhibitors have also brought significant benefit to patients. More recently, treatments restoring adaptive anti-tumor immunity, anti-program death 1 (anti-PD-1) checkpoint inhibitors (ICP), have in turn revolutionized the management of patients with mRCC. The multi-tumor efficacy of these ICPs proves the crucial role of anti-tumor immunity in tumor development and progression in a number of tumors including clear cell kidney tumours (ccRCC). The tumor immune microenvironment (TME) of ccRCC is known to be highly immunosuppressive. Thus ccRCCs are characterized by a strong infiltration of CD8+ T lymphocytes, frequently expressing immunological checkpoint molecules on their surface, giving them a poor prognostic feature. These characteristics partly explain the effectiveness of ICP in ccRCC and constitute a strong rationale for their further development, either at an earlier stage or in combination, particularly with AA or TKI. In this review are compiled the main clinical results of immunological checkpoint molecules alone or in combination in 1stline or after TKI failure.
Collapse
Affiliation(s)
- Yann-Alexandre Vano
- Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Inserm, UMRS 1138, Centre de recherche des cordeliers, cancer et immunité antitumorale, université Paris-Descartes, Sorbonne-Paris-Cité, F-75006, Paris, France.
| | - Audrey Simonaggio
- Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Inserm, UMRS 1138, Centre de recherche des cordeliers, cancer et immunité antitumorale, université Paris-Descartes, Sorbonne-Paris-Cité, F-75006, Paris, France
| | - Constance Thibault
- Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Inserm, UMRS 1138, Centre de recherche des cordeliers, cancer et immunité antitumorale, université Paris-Descartes, Sorbonne-Paris-Cité, F-75006, Paris, France
| | - Stéphane Oudard
- Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Immunothérapies et antiangiogéniques en oncologie, équipe 10 PARCC, INSERM U970, Sorbonne-Paris-Cité, Paris, France
| |
Collapse
|
6
|
Trivin-Avillach C, Thervet É. [Immunizations for patients with kidney disease]. Nephrol Ther 2018; 15:233-240. [PMID: 29887267 DOI: 10.1016/j.nephro.2017.11.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Revised: 10/23/2017] [Accepted: 11/19/2017] [Indexed: 12/18/2022]
Abstract
Chronic kidney disease (CKD) is associated with significant infectious complications leading to adverse health outcomes. This increased susceptibility to infection can be related to the nephropathy itself as observed in nephrotic syndrome, to the treatment especially in situations requiring immunosuppressive drugs or related to dialysis. Despite a less effective response to vaccination, some data emphasize similar benefits from immunization among people with CKD to the general population. However, some situations encountered in nephrology require adaptation of immunization practices. The aim of this review is to provide a synthesis of the existing guidelines for immunization in the field of nephrology.
Collapse
Affiliation(s)
| | - Éric Thervet
- Service de néphrologie, université Paris-Descartes, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
| |
Collapse
|
7
|
Nesseler JP, Schaue D, McBride WH, Nickers P. [Inflammatory and immune biomarkers of radiation response]. Cancer Radiother 2018; 22:180-192. [PMID: 29650389 DOI: 10.1016/j.canrad.2017.09.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Accepted: 09/08/2017] [Indexed: 02/07/2023]
Abstract
In radiotherapy, the treatment is adapted to each individual to protect healthy tissues but delivers most of time a standard dose according to the tumor histology and site. The only biomarkers studied to individualize the treatment are the HPV status with radiation dose de-escalation strategies, and tumor hypoxia with dose escalation to hypoxic subvolumes using FMISO- or FAZA-PET imaging. In the last decades, evidence has grown about the contribution of the immune system to radiation tumor response. Many preclinical studies have identified some of the mechanisms involved. In this context, we have realised a systematic review to highlight potential inflammatory and immune biomarkers of radiotherapy response. Some are inside the tumor microenvironment, as lymphocyte infiltration or PD-L1 expression, others are circulating biomarkers, including different types of hematological cells, cytokines and chemokines.
Collapse
Affiliation(s)
- J P Nesseler
- Department of radiation oncology, David Geffen school of medicine, university of California at Los Angeles, 10833 Le Conte avenue, 90095-1714 Los Angeles, CA, États-Unis.
| | - D Schaue
- Department of radiation oncology, David Geffen school of medicine, university of California at Los Angeles, 10833 Le Conte avenue, 90095-1714 Los Angeles, CA, États-Unis
| | - W H McBride
- Department of radiation oncology, David Geffen school of medicine, university of California at Los Angeles, 10833 Le Conte avenue, 90095-1714 Los Angeles, CA, États-Unis
| | - P Nickers
- Départment de radiothérapie, centre François-Baclesse, rue Émile-Mayrisch, 4240 Esch-sur-Alzette, Luxembourg
| |
Collapse
|
8
|
Abstract
The evolutionary history of modern humans means much more than their demographic past. It includes the way in which humans have had to genetically adapt to the different environments they have encountered-nutritional, climatic or pathogenic-as well as the different epigenetic responses elicited by such environmental cues. Detecting how natural selection has affected human genome variability has proven to be a powerful tool to delineate genes and biological functions having played a key role in human adaptation, a variation which can also be involved in phenotypes of medical relevance. This article reviews several examples that illustrate well how different environmental pressures, particularly those imposed by pathogens and infectious diseases, have shaped the patterns of genetic and epigenetic variability currently observed in human populations.
Collapse
Affiliation(s)
- Lluis Quintana-Murci
- Unit of Human Evolutionary Genetics, CNRS URA3012, Institut Pasteur, 25-28, rue du Docteur-Roux, 75015 Paris, France.
| |
Collapse
|
9
|
Meckenstock R, Therby A. [Modifications of immunity in obesity: The impact on the risk of infection]. Rev Med Interne 2015; 36:760-8. [PMID: 26410420 DOI: 10.1016/j.revmed.2015.07.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Revised: 05/13/2015] [Accepted: 07/25/2015] [Indexed: 12/28/2022]
Abstract
Incidence of obesity is constantly rising all over the world; obesity has developed into an important problem of public health. Clinical experience, supported by many clinical trials, shows that obesity constitutes a risk factor for numerous cardiovascular, metabolic, cancer and even infectious diseases. In this revue we summarize the present knowledge on immunological properties and functions of adipose tissue and their modifications in obese subjects, with a bending to a potentially deleterious chronic inflammatory state. We will discuss the negative impact of this chronic inflammation on physiological acute inflammatory reaction during infectious episodes. However, the modifications of anti-infectious immune response in obese subjects are not well known at present and need further investigations.
Collapse
Affiliation(s)
- R Meckenstock
- Service de médecine interne et de maladies infectieuses, centre hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France.
| | - A Therby
- Service de médecine interne et de maladies infectieuses, centre hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France
| |
Collapse
|
10
|
Gentili ME. [Early human transplants: 60th anniversary of the first successful kidney transplants]. Nephrol Ther 2015. [PMID: 26206772 DOI: 10.1016/j.nephro.2015.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
First kidney transplant attempts begin with the 20th century: improving vascular sutures, understanding the phenomena of rejection or tolerance, then progress in HLA groups enable early success in the second half of the century. Definition of brain death, use of corticosteroids, radiotherapy and prime immunosuppressors promote the development of transplants. Discover of cyclosporine in the 1980s, and legislative developments augur a new era. Many advances are arising: use of stem cells from the donor, enhancement of Maastricht 3 donor or living donation. Finally organ transplantation remains an immense human adventure, but also scientific and ethic.
Collapse
Affiliation(s)
- Marc E Gentili
- Département d'anesthésie-réanimation, centre hospitalier privé Saint-Grégoire, 35760 Saint-Grégoire, France.
| |
Collapse
|
11
|
Abstract
The discovery and understanding of complex cellular interactions that govern the immune system contributed to the pharmacological targeting of anti-tumor immunity. The activity of immune effector cells, such as NK and T-cells, is regulated by a wide range of activating and inhibiting receptors or ligands. Drugs that target these receptors or ligands can modulate the immune response by exerting antagonistic or agonistic effects. Over the past decade, several immunomodulators have demonstrated clinical effectiveness, and three of them have already been approved for use in oncology. The development of these immunotherapy approaches presented unique challenges for safety and efficacy, requiring revising clinical response criteria and the establishment of guidelines to help oncologists to manage properly inflammatory toxicities. The introduction of these immunotherapies is a revolution in oncology. However, additional efforts in terms of optimizing treatment administration and identification of biomarkers are needed. Identifying the immunodynamics of various immunomodulators should allow a better understanding of anti-tumor and inflammatory mechanisms, and certainly give the opportunity to develop effective therapeutic combinations without potentiating adverse events.
Collapse
Affiliation(s)
- Mélanie Desbois
- Gustave-Roussy cancer campus, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Gustave-Roussy cancer campus, centre d'investigation clinique biothérapie 1428, Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Université Paris-Sud, faculté de médecine, 63, rue Gabriel-Péri, 94270 Kremlin-Bicêtre, France; Gustave-Roussy cancer campus, laboratoire d'immunomonitoring en oncologie, UMS 3655 CNRS et US 23 Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France
| | - Stéphane Champiat
- Gustave-Roussy cancer campus, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Gustave-Roussy cancer campus, département des innovations thérapeutiques et d'essais précoces (DITEP), 39, rue Camille-Desmoulins, 94805 Villejuif, France; Institut de cancérologie de l'Ouest, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - Nathalie Chaput
- Gustave-Roussy cancer campus, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Gustave-Roussy cancer campus, centre d'investigation clinique biothérapie 1428, Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Gustave-Roussy cancer campus, laboratoire d'immunomonitoring en oncologie, UMS 3655 CNRS et US 23 Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
| |
Collapse
|
12
|
Sun R, Sbai A, Ganem G, Boudabous M, Collin F, Marcy PY, Doglio A, Thariat J. [Non-targeted effects (bystander, abscopal) of external beam radiation therapy: an overview for the clinician]. Cancer Radiother 2014; 18:770-8. [PMID: 25451674 DOI: 10.1016/j.canrad.2014.08.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Revised: 07/21/2014] [Accepted: 08/05/2014] [Indexed: 11/19/2022]
Abstract
Radiotherapy is advocated in the treatment of cancer of over 50 % of patients. It has long been considered as a focal treatment only. However, the observation of effects, such as fatigue and lymphopenia, suggests that systemic effects may also occur. The description of bystander and abscopal effects suggests that irradiated cells may exert an action on nearby or distant unirradiated cells, respectively. A third type of effect that involves feedback interactions between irradiated cells was more recently described (cohort effect). This new field of radiation therapy is yet poorly understood and the definitions suffer from a lack of reproducibility in part due to the variety of experimental models. The bystander effect might induce genomic instability in non-irradiated cells and is thus extensively studied for a potential risk of radiation-induced cancer. From a therapeutic perspective, reproducing an abscopal effect by using a synergy between ionizing radiation and immunomodulatory agents to elicit or boost anticancer immune responses is an interesting area of research. Many applications are being developed in particular in the field of hypofractionated stereotactic irradiation of metastatic disease.
Collapse
Affiliation(s)
- R Sun
- Département de radiothérapie, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - A Sbai
- Centre régional d'oncologie Hassan-II, BP 2013, Oued Nachef, Oujda, Maroc
| | - G Ganem
- Centre Jean-Bernard, clinique Victor-Hugo, 9, rue Beauverger, 72000 Le Mans, France
| | - M Boudabous
- Université Nice-Sophia Antipolis, 33, avenue Valombrose, 06189 Nice, France
| | - F Collin
- UMR 152 Pharma-Dev, université Toulouse-3, 31062 Toulouse cedex 09, France; UMR 152 Pharma-Dev, institut de recherche pour le développement (IRD), 31062 Toulouse cedex 09, France
| | - P-Y Marcy
- Département de radiologie, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice, France
| | - A Doglio
- Unité de thérapie cellulaire et génique, faculté de médecine, université Nice-Sophia Antipolis, 33, avenue Valombrose, 06189 Nice, France
| | - J Thariat
- Université Nice-Sophia Antipolis, 33, avenue Valombrose, 06189 Nice, France; Département de radiothérapie, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France.
| |
Collapse
|
13
|
Cinotti R, Roquilly A, Mahé PJ, Demeure-Dit-Latte D, Chupin AM, Josse-Chatel N, Peneau C, Paulus J, Lejus C, Asehnoune K. Operative care and surveillance in severe trauma patients. Interference between resuscitation treatments and anaesthesiology, and consequence on immunity. ACTA ACUST UNITED AC 2013; 32:516-9. [PMID: 23916514 DOI: 10.1016/j.annfar.2013.07.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Major trauma remains a worldwide cause of morbi-mortality. Early mortality is the consequence of hemorrhagic shock and traumatic brain injury. During early resuscitation, anaesthesia is often mandatory to perform surgery. It is mandatory to master the hemodynamic effects of hypnotic drugs in order to anticipate their potential deleterious effects in the setting of hemorrhagic shock. After early resuscitation, trauma patients present a high prevalence of nosocomial pneumonia, which sustains major morbidity. Nosocomial pneumonia are the consequence of an overwhelming systemic inflammatory response syndrome (SIRS) as well as a trauma-related immunosuppression. The administration of hemisuccinate of hydrocortisone modulates the SIRS and reduces the risk of nosocomial pneumonia as well as the length of mechanical ventilation. Finally in the operating theatre, fighting against hypothermia and un-anatomical positions, which can aggravate rhabdomyolysis, are both mandatory.
Collapse
|